Skip to main content
NewslettersWatchlist

Celldex Therapeutics(CLDX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low40.20
Day High43.35
Open:41.07
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why Celldex Therapeutics Blasted 13% Higher on Monday
TheNewswire.com
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Globe Newswire
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update
TipRanks
Billionaire Andreas Halvorsen Bets Big on These 2 High-Upside Stocks
TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX) and Intercept Pharma (ICPT)
TipRanks
SVB Securities Thinks Celldex’s Stock is Going to Recover
Globe Newswire
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
Globe Newswire
Celldex Announces Two New Appointments to its Board of Directors
Globe Newswire
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
Globe Newswire
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
Globe Newswire
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Globe Newswire
Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call
Globe Newswire
Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Globe Newswire
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis
Globe Newswire
Celldex to Participate in Upcoming Investor Conferences
Globe Newswire
Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
Globe NewsWire
Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
Globe NewsWire
Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
Globe NewsWire
Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
Globe NewsWire
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Globe NewsWire
Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
Globe NewsWire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
Globe NewsWire
Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
Globe NewsWire
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
Globe NewsWire
Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021
Globe NewsWire
Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference
Globe NewsWire
Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
Globe NewsWire
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results

Profile

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.